stockrow
Friday 6 November 2026
Export DFTX’s income statement to Excel — free account
Definium Therapeutics, Inc.
DFTX Healthcare Biotechnology
- EPS
- −188.0%
- Free cash flow
- −78.3%
- Total debt
- −11.5%
Quarter to June 2026, against a year earlier
33.27
2.91
+9.58%
Follow DFTX
Alert me
Definium Therapeutics, Inc. (DFTX) EBITDA
Definium Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$168.1M, compared with −$103.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$227.7M. Over the past ten years it has ranged from −$168.1M (fiscal 2025) to −$628.9K (fiscal 2018) — the current reading is the lowest in ten years. EBITDA has fallen for 3 consecutive fiscal years. Definium Therapeutics, Inc. ranks 527th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$168.1M | — |
| FY2024 | −$103.4M | — |
| FY2023 | −$90.6M | — |
| FY2022 | −$63.2M | — |
| FY2021 | −$91.2M | — |
| FY2020 | −$33.0M | — |
| FY2019 | −$10.7M | — |
| FY2018 | −$628.9K | — |
| FY2017 | −$983.7K | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$76.4M | — |
| Mar 2026 | −$58.6M | — |
| Dec 2025 | −$47.1M | — |
| Sep 2025 | −$45.5M | — |
| 24 more quarters | Free account |
Against its own ten years
Low −$168.1M
High −$628.9K
Ten-year median
−$63.2M
Current reading's percentile
11
EBITDA against peers
| Company | EBITDA |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | $36.9M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$19.0M |
| TNGX Tango Therapeutics, Inc. compare | −$137.8M |
| ABCL AbCellera Biologics Inc. compare | −$192.6M |
| EWTX Edgewise Therapeutics, Inc. compare | −$221.9M |
| DNTH Dianthus Therapeutics, Inc. compare | −$227.5M |
| DFTX Definium Therapeutics, Inc. | −$227.7M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$261.9M |
| RLAY Relay Therapeutics, Inc. compare | −$311.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item